Disc MedicineIRON +1.73%34 9-Day RSI is 71.90 as of Jul. 05, 2026. GuruFocus rates IRON with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,418 Biotechnology companies, Disc Medicine ranks worse than 86.81% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-05), Disc Medicine's 9-Day RSI is 71.90.
The industry rank for Disc Medicine's 9-Day RSI or its related term are showing as below:
IRON's 9-Day RSI is ranked worse than 86.81% of 1418
companies
in the Biotechnology industry
Industry Median: 53.73
vs IRON: 71.90
Disc Medicine (NAS:IRON) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Disc Medicine 9-Day RSI Related Terms
IRON vs CLDX, TARS, KLRA: 9-Day RSI Comparison
For the Biotechnology subindustry, Disc Medicine's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Disc Medicine 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Disc Medicine's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Disc Medicine's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Disc Medicine (IRON) has a 9-Day RSI of 71.90 as of Jul. 05, 2026. According to the industry distribution chart, Disc Medicine ranks #1231 out of 1418 companies in the Biotechnology industry, placing it in the top 86.8%.
Is Disc Medicine's 9-Day RSI too high?
Disc Medicine's current 9-Day RSI is 71.90. The Biotechnology industry median 9-Day RSI is 53.73. Disc Medicine's value of 71.90 is 33.8% above this industry median. Based on the distribution chart, Disc Medicine ranks #1231 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Disc Medicine has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Disc Medicine's 9-Day RSI compare to CLDX and TARS?
According to the Biotechnology industry distribution chart, Disc Medicine ranks #1231 out of 1418 companies for 9-Day RSI. This places Disc Medicine in the lower half of its industry. The industry median 9-Day RSI is 53.73. Disc Medicine's value of 71.90 is 33.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 53.73, based on 1,418 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Disc Medicine's current 9-Day RSI of 71.90 is 33.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 53.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Disc Medicine's current 9-Day RSI is 71.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disc Medicine stock overvalued right now?
Disc Medicine (IRON) has a current 9-Day RSI of 71.90. The current 9-Day RSI is 71.90 and 33.8% above the Biotechnology industry median of 53.73. Disc Medicine's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Disc Medicine (IRON), the current 9-Day RSI is 71.90 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
34GF Score
Get the complete analysis for IRON
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRON has been successfully added to your 